Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is poised for significant growth driven by its strategic expansion into the companion animal diagnostic market, particularly with the anticipated introduction of a feline assay that could potentially double its addressable market. The company has successfully initiated revenue generation from its CE-Marked Nu.Q NETs automated assay and has expanded its evaluations to numerous hospitals globally, enhancing its visibility and clinical effectiveness in the human diagnostics space. Furthermore, strategic partnerships with established players like Werfen and Hologic illustrate the company's efforts to scale its human diagnostics licensing strategy, while advancements in its scientific platform bolster both its appeal and operational reach across targeted sectors.

Bears say

VolitionRX Ltd is facing heightened dilution risk, which has prompted a reduction in future price projections from $5.00 to $3.00. The company’s reliance on its Nucleosomics platform for developing blood tests poses financial challenges, particularly as it navigates the costs associated with research and development in an environment where funding may be uncertain. This increased risk and reduced valuation reflect broader concerns about the company's financial health and its ability to achieve sustainable growth within a competitive diagnostics market.

Volitionrx Limited (VNRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.